Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Protara Therapeutics (NASDAQ:TARA) and raises the price target from $26 to $30.

April 22, 2024 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on Protara Therapeutics and raises the price target from $26 to $30.
The upgrade in price target by a reputable analyst like Leland Gershell from Oppenheimer is a strong positive signal for Protara Therapeutics. It suggests confidence in the company's future performance and potential for stock price appreciation. Such endorsements often lead to increased investor interest and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100